Zimmer Biomet (NYSE:ZBH) Stock Rating Lowered by TheStreet

Zimmer Biomet (NYSE:ZBH) was downgraded by equities researchers at TheStreet from a “b-” rating to a “c+” rating in a research note issued to investors on Friday, November 24th.

Several other equities research analysts have also recently weighed in on ZBH. Jefferies Group reaffirmed a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. Stifel Nicolaus reiterated a “hold” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a report on Friday, November 3rd. Gabelli initiated coverage on shares of Zimmer Biomet in a report on Thursday, August 24th. They issued a “buy” rating and a $142.00 price objective for the company. Zacks Investment Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Finally, SunTrust Banks reissued a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a research report on Monday, October 2nd. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $133.71.

Shares of Zimmer Biomet (NYSE ZBH) opened at $115.78 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The company has a market cap of $23,383.62, a price-to-earnings ratio of 14.31, a PEG ratio of 1.79 and a beta of 1.15. Zimmer Biomet has a 1 year low of $100.81 and a 1 year high of $133.49.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same period last year, the company posted $1.79 earnings per share. The business’s revenue was down .8% compared to the same quarter last year. research analysts forecast that Zimmer Biomet will post 8.03 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Bronfman E.L. Rothschild L.P. grew its stake in shares of Zimmer Biomet by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Zimmer Biomet by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after acquiring an additional 33 shares during the last quarter. Bank of Nova Scotia Trust Co. purchased a new stake in shares of Zimmer Biomet in the third quarter worth $112,000. FNY Managed Accounts LLC purchased a new stake in shares of Zimmer Biomet in the third quarter worth $117,000. Finally, BB&T Investment Services Inc. purchased a new stake in shares of Zimmer Biomet in the second quarter worth $144,000. Institutional investors own 86.24% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.thelincolnianonline.com/2017/12/07/zimmer-biomet-holdings-inc-zbh-lowered-to-c-at-thestreet-updated-updated.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply